Help For Irritable Bowel Syndrome (IBS) - Education, Support, & Self Help for Irritable Bowel Syndrome
Heather & Company View Cart
Shop for IBSIBS Message BoardsIBS News & ReviewsStore Finder
IBS Diet & Recipes
IBS Books
IBS Supplements
Yoga for IBS
Hypnosis for IBS
Tummy Teas
Get The IBS Diet Cheat Sheet
Get Trigger Foods, Safe Foods, Ten Commandments of Eating for IBS, More!

Enter First Name:

Enter Email:

We value your privacy

All Boards >> Irritable Bowel Syndrome Research Library


Reged: 12/09/02
Posts: 7674
Loc: Seattle, WA
Rifaximin vs Placebo in Reducing Symptoms in Adults With IBS
      11/26/06 02:39 PM

Efficacy of Rifaximin vs Placebo in Reducing Symptoms in Adults With IBS

David A. Johnson, MD, FACG, FACP

The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome: A Randomized Trial
Pimentel M, Park S, Mirocha J, Kane SV, Kong Y

Ann Intern Med. 2006;145:557-563

Irritable bowel syndrome (IBS) is a prevalent condition that has been labeled as a "functional bowel disorder." By this delineation, its cause has been thought to be indefinable. The primary symptoms of this disorder include constipation, diarrhea, abdominal bloating, and cramping. Recent attention has focused on a potential infectious component of IBS.

In this study, Pimental and colleagues investigated the use of rifaximin in patients diagnosed with IBS as defined by the Rome I criteria. Rifaximin is a nonabsorbable, gut-selective antibiotic derived from the rifamycin family that may reduce bacterial overgrowth due to its broad-spectrum activity in vitro against gram-positive, gram-negative, aerobic, anaerobic, and microaerophilic bacteria.

This was a prospective, double-blind randomized controlled trial that involved 43 patients who received 400 mg of rifaximin 3-times daily and 44 who received placebo for 10 days. Patient symptom and stool diaries were completed prior to entry, during the study, and the week following treatment.

Global improvement was found to vary widely across weeks for most patients, and the data were reported as an averaging of the symptoms over all 10 weeks of the study. This percentage was significant as a function of group (P = .020), but not as a function of week (P = .78) or group-by-week (P = .96). The patients in the rifaximin group had a 36.4% improvement in global symptoms compared with 21.0% for the placebo group.

The rifaximin group also reported significantly less bloating on a visual analog scale compared with the placebo group (P = .010), a difference that persisted after controlling for differences between groups in baseline pain scores (P = .001). Besides bloating, none of the secondary endpoints improved with treatment compared with placebo on the visual analog scale: abdominal pain (P = .32), diarrhea (P = .67), and constipation (P = .069).

Rifaximin is currently US Food and Drug Administration-approved for the treatment of traveler's diarrhea, although these study findings suggest a more expanded potential role for this antibiotic. However, before recommending widespread globalized use of this medication for all patients with IBS, healthcare providers should be aware of several limitations of this study. First, although this was a "multicenter study," there was a considerable imbalance between enrollment from the 2 study sites (83 participants vs 3 participants). Second, because the global measure includes pain, it is important to note that there was an imbalance in baseline pain scores between the 2 patient groups at entry. The imbalance (higher baseline pain scores in the rifaximin group) potentially favors the reduction in the global scores. Additionally, this primary outcome measure is unique in the spectrum of the recent treatment intervention evaluations for IBS trials, and therefore makes comparisons with other trials somewhat difficult. Third, the study authors relied solely on the use of the lactose breath test to define small bowel bacterial overgrowth. Future tests in this area should evaluate the use of other breath tests to define bacterial overgrowth in the small intestine. Fourth, the data suggest that rifaximin may be of more help in the subset of patients with bloating. In IBS, abdominal bloating is reported in more than 50% of patients, and a recent study suggests that changes in abdominal girth can reach 12 cm in more than 50% of patients.[1]

Clearly, this study highlights a new concept in the potential pathogenesis of IBS. An infectious cause may offer a tremendous opportunity to manage an otherwise somewhat frustrating disease -- both for patients and their treating physicians.


Houghton LA, Lea R, Agrawal A, Reilly B, Whorwell PJ. Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit. Gastroenterology. 2006;131:1003-1010.

David A. Johnson, MD, FACG, FACP, Professor of Medicine, Chief of Gastroenterology, Eastern Virginia School of Medicine, Norfolk, Virginia

David A. Johnson, MD, FACG, FACP, has disclosed that he has received grants for clinical research from AstraZeneca, TAP, Wyeth, Novartis, and Abbott, and grants for educational activities from AstraZeneca and Novartis. Dr. Johnson has also disclosed that he has served as an advisor or consultant to AstraZeneca, TAP, and Novartis.

Medscape Gastroenterology. 2006;8(2) ©2006 Medscape

Heather is the Administrator of the IBS Message Boards. She’s the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Post Extras Print Post   Remind Me!     Notify Moderator

Entire thread
Subject Posted by Posted on
* Pharmaceutical HeatherAdministrator 07/14/03 01:50 PM
. * Long-term cannabis use increases risk for IBS HeatherAdministrator   10/19/17 04:04 PM
. * FDA approves new drug for chronic constipation HeatherAdministrator   01/26/17 03:05 PM
. * Mixed Opioid Agent Adds to Growing List of Therapies for IBS-D HeatherAdministrator   01/27/16 02:48 PM
. * Low-dose naltreoxone for the treatment of irritable bowel syndrome HeatherAdministrator   01/26/16 01:20 PM
. * Amitiza benefited patients with chronic idiopathic constipation HeatherAdministrator   02/10/15 04:15 PM
. * Medical Marijuana for Digestive Disorders: High Time to Prescribe? HeatherAdministrator   09/17/14 02:08 PM
. * Antibiotics Early in Life May Boost Obesity Risk HeatherAdministrator   08/18/14 03:13 PM
. * Antidepressants, psychological therapies effectively treated IBS HeatherAdministrator   07/15/14 02:49 PM
. * Proton pump inhibitor (acid reflux drugs) may cause heart disease HeatherAdministrator   09/23/13 03:22 PM
. * Older drugs are better than new ones HeatherAdministrator   06/13/13 02:00 PM
. * On Anti-Depressants? Some Raise Risk of C. Diff Infection HeatherAdministrator   05/13/13 05:51 PM
. * Heartburn drugs, NSAID painkillers use linked to IBS symptoms HeatherAdministrator   03/18/13 01:24 PM
. * FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation HeatherAdministrator   08/31/12 11:25 AM
. * 3-month FDA delay for potential IBS drug linaclotide HeatherAdministrator   04/23/12 01:45 PM
. * Latest FDA watch list includes GI drugs HeatherAdministrator   04/23/12 01:42 PM
. * Antibiotics that reduce gut bacteria linked to obesity HeatherAdministrator   05/06/11 12:25 PM
. * Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases HeatherAdministrator   02/10/11 10:23 AM
. * Antacids increase risk of pneumonia HeatherAdministrator   01/14/11 04:35 PM
. * Editorial - Antibiotic Rifaximin (Xifaxan) Therapy for the Irritable Bowel Syndrome HeatherAdministrator   01/07/11 03:01 PM
. * Antiobiotic Rifaximin (Xifaxan) for Patients with Irritable Bowel Syndrome without Constipation HeatherAdministrator   01/07/11 02:59 PM
. * Proton Pump Inhibitor Drugs Tied to 80% Increase in Clostridium difficile Risk HeatherAdministrator   11/10/10 11:29 AM
. * Phase 3 clinical trials of linaclotide for IBS constipation HeatherAdministrator   10/13/10 02:44 PM
. * An over-the-counter drug for constipation offers superior symptom relief compared with a commonly used prescription agent HeatherAdministrator   07/16/10 03:17 PM
. * Benefit/risk ratio of Renzapride not sufficient to warrant further study in IBS-C HeatherAdministrator   04/07/10 01:32 PM
. * Adverse effects of drugs on small intestine and colon HeatherAdministrator   03/16/10 11:23 AM
. * Children's Belly Aches Don't Disappear With Antidepressant HeatherAdministrator   03/11/10 01:14 PM
. * Survey: Marijuana Use In Patients With IBS HeatherAdministrator   01/12/10 03:17 PM
. * FDA Approves Amitiza for IBS-C HeatherAdministrator   05/23/08 10:59 AM
. * Zelnorm no longer available except for emergency use HeatherAdministrator   04/11/08 12:05 PM
. * Clinical trial: phase 2 trial of lubiprostone for irritable bowel syndrome with constipation. HeatherAdministrator   02/15/08 11:20 AM
. * Role of Antibiotics vs Conventional Pharmacotherapy in Treating Symptoms of Irritable Bowel Syndrome HeatherAdministrator   01/03/08 04:45 PM
. * FDA permits the restricted use of Zelnorm HeatherAdministrator   08/09/07 11:41 AM
. * Antidepressant Therapy (Imipramine and Citalopram) for Irritable Bowel Syndrome HeatherAdministrator   06/20/07 01:56 PM
. * Neuromuscular Dysfunction and IBS: Clinical Implications for Drug Use HeatherAdministrator   02/04/07 04:30 PM
. * Enteric Bacteria and IBS HeatherAdministrator   11/26/06 02:51 PM
. * Rifaximin vs Placebo in Reducing Symptoms in Adults With IBS HeatherAdministrator   11/26/06 02:39 PM
. * Antibiotic Rifaximin Appears Safe and Effective for Irritable Bowel Syndrome HeatherAdministrator   10/26/06 10:29 AM
. * Citalopram (Celexa) Improves Symptoms of Irritable Bowel Syndrome HeatherAdministrator   10/14/06 12:57 PM
. * Marijuana eases chronic pain HeatherAdministrator   07/17/06 11:49 AM
. * Doctors group launches war on drug ads HeatherAdministrator   07/17/06 11:17 AM
. * New IBS drug in development in Japan HeatherAdministrator   07/05/06 05:13 PM
. * Marijuana and the gastrointestinal tract HeatherAdministrator   06/12/06 03:38 PM
. * Zelnorm Rejected Again in Europe HeatherAdministrator   04/02/06 03:25 PM
. * Antidepressants for IBS HeatherAdministrator   03/16/06 12:31 PM
. * Takeda Laxative Wins U.S. Approval for Adults HeatherAdministrator   02/18/06 01:36 PM
. * Cilansetron: ; Solvay Pharmaceuticals suspends registration activites in the U.S., HeatherAdministrator   01/18/06 04:15 PM
. * Hearburn Drugs Cause Diarrhea HeatherAdministrator   01/08/06 05:10 PM
. * Zelnorm fails to win EU panel backing HeatherAdministrator   12/21/05 11:25 AM
. * Non-steroidal anti-inflammatory drugs and gastrointestinal damage HeatherAdministrator   12/08/05 12:51 PM
. * Octreotide May Be Effective in Treatment of Nonconstipated IBS HeatherAdministrator   12/08/05 12:31 PM
. * Lack of Lasting Effectiveness of Miralax Laxative Treatment of Constipation. HeatherAdministrator   08/07/05 04:18 PM
. * Acute Hepatitis Associated With Lotronex HeatherAdministrator   07/24/05 02:37 PM
. * FDA revisions to safety labeling for Lotronex (alosetron ) HeatherAdministrator   05/22/05 06:46 PM
. * Clinical pharmacology of new motility promoting agents HeatherAdministrator   05/22/05 06:33 PM
. * Rationale for Using Serotonergic Agents to Treat Irritable Bowel Syndrome HeatherAdministrator   05/08/05 06:21 PM
. * Zelnorm Associated With Rare Cases of Severe Diarrhea, Ischemic Colitis HeatherAdministrator   04/24/05 03:48 PM
. * Clinical Response to Tricyclic Antidepressants in Functional Bowel Disorders not Related to Dosage HeatherAdministrator   03/28/05 01:32 PM
. * Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant IBS HeatherAdministrator   02/19/05 05:56 PM
. * Irritable Bowel Syndrome Medications Side Effects Survey HeatherAdministrator   11/09/04 02:04 PM
. * On the Relationship Between Colon Ischemia, Irritable Bowel Syndrome, and Serotonergic Therapy of Irritable Bowel Syndrome HeatherAdministrator   10/24/04 07:10 PM
. * New Risk Information on Zelnorm for IBS for Women HeatherAdministrator   07/11/04 02:18 PM
. * The Relationship among Previous Antimicrobial Use and H. Pylori Infections HeatherAdministrator   06/27/04 01:33 PM
. * Therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome HeatherAdministrator   06/04/04 03:54 PM
. * Pharmaceutical companies funding a number of studies into IBS in the UK HeatherAdministrator   05/25/04 12:00 PM
. * Irritable bowel syndrome helped by Paroxetine, a drug for depression HeatherAdministrator   05/10/04 02:15 PM
. * Fears cause low sales of Lotronex HeatherAdministrator   05/10/04 01:46 PM
. * Zelnorm Warning Issued by FDA HeatherAdministrator   05/10/04 01:01 PM
. * Renzapride Improves Symptoms in Constipation-Predominant Irritable Bowel Syndrome HeatherAdministrator   12/01/03 06:14 PM
. * Clinical Trial Guidelines for Pharmacological Treatment of IBS - Pharmacological Options HeatherAdministrator   12/01/03 05:55 PM
. * SOLVAY presses ahead with cilansetron, a new IBS drug HeatherAdministrator   11/18/03 03:43 PM
. * Measuring Treatment Effects in IBS Trials HeatherAdministrator   10/20/03 03:30 PM
. * FDA Orders Novartis To Pull Zelnorm Ads HeatherAdministrator   10/07/03 11:25 PM
. * Step-down dosage of PPI drugs for hearburn HeatherAdministrator   09/30/03 01:26 PM
. * Evaluation of drug treatment in irritable bowel syndrome HeatherAdministrator   09/30/03 12:52 PM
. * Pain Relievers and Intestinal Disorders HeatherAdministrator   09/16/03 04:20 PM
. * Hypersensitivity and hyperreactivity in IBS: opportunity for drug discovery HeatherAdministrator   07/18/03 12:39 PM
. * Antidepressants in the Treatment of IBS and Other Functional GI Disorders HeatherAdministrator   07/18/03 12:20 PM
. * Use of Antidepressants in the Treatment of IBS? HeatherAdministrator   07/14/03 03:58 PM
. * Combined use of SSRIs and NSAIDs increases the risk of GI adverse effects HeatherAdministrator   07/14/03 03:15 PM

Extra information
0 registered and 95 anonymous users are browsing this forum.

Moderator:  Heather 

      You cannot post until you login
      You cannot reply until you login
      HTML is enabled
      UBBCode is enabled

Thread views: 329801

Jump to

| Privacy statement Help for IBS Home

UBB.threads™ 6.2

LEGAL DISCLAIMER - This website is not intended to replace the services of a physician, nor does it constitute a doctor-patient relationship. Information on this web site is provided for informational purposes only and is not a substitute for professional medical advice. You should not use the information on this web site for diagnosing or treating a medical or health condition. If you have or suspect you have an urgent medical problem, promptly contact your professional healthcare provider.

Any application of the recommendations in this website is at the reader's discretion. Heather Van Vorous,, and Heather & Company for IBS, LLC are not liable for any direct or indirect claim, loss or damage resulting from use of this website and/or any web site(s) linked to/from it. Readers should consult their own physicians concerning the recommendations on these message boards.

Home | Shop for IBS | IBS Message Boards | IBS News & Reviews
IBS Diet & Recipes | IBS Books | IBS Supplements | Yoga for IBS | Hypnosis for IBS
IBS Tummy Teas | Irritable Bowel Syndrome Glossary

About Us | IBS Links | Search this Site | Site Map | Shipping & Returns | Privacy & Security
Contact Us | For Doctors & Dietitians | Wholesale | Co-packing Services

1999-2009, Heather Van Vorous,, Heather & Company for IBS, LLC.
All information & art is proprietary and may not be duplicated.
All rights reserved.

Legal & Medical Disclaimer

Website Design